The FDA maintains burdensome, medically unnecessary restrictions on mifepristone, which is used in combination with another medication—misoprostol—for early pregnancy termination. This combination of medications is safer than Viagra and Tylenol and is now used in approximately two-thirds of all abortions in the United States.
Over the last decade, the FDA has removed some of the restrictions on mifepristone, including a requirement that the medication be dispensed in person by doctors, but the agency still requires prescribers and pharmacies to register with the drug maker and requires patients to sign a counseling form with redundant, inaccurate and confusing information, all of which has decreased access to the medication.
To remove these requirements, the Center for Reproductive Rights filed a lawsuit in May 2023, Whole Woman’s Health Alliance v. U.S. Food and Drug Administration, asking a federal district court in Charlottesville, Va., to order the FDA to lift these restrictions on mifepristone.
On Monday, May 19, 2025, the court heard oral arguments on cross motions for summary judgment in the case. “The Trump administration has made it clear that they do not care about science, or our health and safety,” said CRR on social media. “They only care about taking away our rights. But we refuse to let that happen. We’re ALL IN on this fight.”